Ipsen SA, of Paris, said the New England Journal of Medicine published clinical results showing that Somatuline Autogel/Somatuline Depot (lanreotide) achieved statistically significant prolongation and progression-free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).